Richard Callaghan
Cited by
Cited by
Communication between multiple drug binding sites on P-glycoprotein
C Martin, G Berridge, CF Higgins, P Mistry, P Charlton, R Callaghan
Molecular pharmacology 58 (3), 624-632, 2000
Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis
MF Rosenberg, R Callaghan, RC Ford, CF Higgins
Journal of Biological Chemistry 272 (16), 10685-10694, 1997
Basis for design and development of platinum (IV) anticancer complexes
MD Hall, HR Mellor, R Callaghan, TW Hambley
Journal of medicinal chemistry 50 (15), 3403-3411, 2007
Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?
R Callaghan, F Luk, M Bebawy
Drug Metabolism and Disposition 42 (4), 623-631, 2014
Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle
MF Rosenberg, G Velarde, RC Ford, C Martin, G Berridge, ID Kerr, ...
The EMBO journal 20 (20), 5615-5625, 2001
Collateral sensitivity as a strategy against cancer multidrug resistance
KM Pluchino, MD Hall, AS Goldsborough, R Callaghan, MM Gottesman
Drug Resistance Updates 15 (1-2), 98-105, 2012
The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein
C Martin, G Berridge, P Mistry, C Higgins, P Charlton, R Callaghan
British journal of pharmacology 128 (2), 403-411, 1999
A bacterial antibiotic-resistance gene that complements the human multidrug-resistance P-glycoprotein gene
HW van Veen, R Callaghan, L Soceneantu, A Sardini, WN Konings, ...
Nature 391 (6664), 291-295, 1998
Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer
S Modok, HR Mellor, R Callaghan
Current opinion in pharmacology 6 (4), 350-354, 2006
Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding
MF Rosenberg, AB Kamis, R Callaghan, CF Higgins, RC Ford
Journal of Biological Chemistry 278 (10), 8294-8299, 2003
Three-dimensional structure of P-glycoprotein: the transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state
MF Rosenberg, R Callaghan, S Modok, CF Higgins, RC Ford
Journal of Biological Chemistry 280 (4), 2857-2862, 2005
Resistance to chemotherapy in cancer: a complex and integrated cellular response
HR Mellor, R Callaghan
Pharmacology 81 (4), 275-300, 2008
Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells
R Callaghan, JR Riordan
Journal of Biological Chemistry 268 (21), 16059-16064, 1993
Structure of the multidrug resistance P-glycoprotein
CF Higgins, R Callaghan, KJ Linton, MF Rosenberg, RC Ford
Seminars in cancer biology 8 (3), 135-142, 1997
How can we best use structural information on P-glycoprotein to design inhibitors?
CA McDevitt, R Callaghan
Pharmacology & therapeutics 113 (2), 429-441, 2007
Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2
CA McDevitt, RF Collins, M Conway, S Modok, J Storm, ID Kerr, RC Ford, ...
Structure 14 (11), 1623-1632, 2006
P‐glycoprotein: so many ways to turn it on
R Callaghan, E Crowley, S Potter, ID Kerr
The Journal of Clinical Pharmacology 48 (3), 365-378, 2008
The importance of cholesterol in maintenance of P-glycoprotein activity and its membrane perturbing influence
A Rothnie, D Theron, L Soceneantu, C Martin, M Traikia, G Berridge, ...
European Biophysics Journal 30, 430-442, 2001
Interaction of tamoxifen with the multidrug resistance P-glycoprotein
R Callaghan, CF Higgins
British journal of cancer 71 (2), 294-299, 1995
Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy
J Walker, C Martin, R Callaghan
European journal of cancer 40 (4), 594-605, 2004
The system can't perform the operation now. Try again later.
Articles 1–20